Abstract
Ovarian cancer (OC) is one of the deadliest cancers, with high relapse and resistance rates despite current treatments. The enzyme nicotinamide phosphoribosyltransferase (NAMPT), particularly in its extracellular form (eNAMPT), plays a key role in tumor processes including DNA repair, proliferation, metastasis, and drug resistance. However, its role in OC remains poorly understood. This project aims to investigate the pathological role of eNAMPT in OC, hypothesizing that it promotes aggressive tumor phenotypes via EMT and stemness modulation. Preliminary data show elevated eNAMPT levels in OC ascitic fluid, indicating its potential as a biomarker. The study is structured in four work packages: WP1 evaluates eNAMPT levels in patient samples and correlates them with clinical outcomes; WP2 and WP3 explore its function using in vitro and in vivo models; WP4 tests the efficacy of an anti-eNAMPT monoclonal antibody (C269). The ultimate goal is to assess eNAMPT as a therapeutic target in OC.
Dettagli del progetto
Responsabile scientifico: Gloria Ravegnini
Strutture Unibo coinvolte:
Dipartimento di Farmacia e Biotecnologie
Coordinatore:
ALMA MATER STUDIORUM - Università di Bologna(Italy)
Contributo totale di progetto: Euro (EUR) 224.000,00
Contributo totale Unibo: Euro (EUR) 112.000,00
Durata del progetto in mesi: 24
Data di inizio
16/10/2023
Data di fine:
28/02/2026
